TCL Archive AACR, NCCR Advocate Five-Year Plan to Reach $10 billion Annual Cancer Budget April 30, 1999
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive L-PAM, Less Than Radical Surgery Results Holding Up, New Breast Cancer Studies Sought September 12, 1975
